The results of study presented European Breast Cancer Conference in Berlin. The treatment was targeted at 453 HER2 positive women with early-stage breast canncer. 45.5 per cent were found cancer free following the combination course before surgery. The response from Herceptin in combination is more than double than that of traditional chemotherapy alone. No serious side-effects were reported, but patients receiving Herceptin should always be monitored closely for potential cardiac problems.
It points to the possiblity that women with this highly aggressive form of breast cancer may find a cure within the next decade.